Los Angeles Capital Management LLC Has $1.44 Million Holdings in Phibro Animal Health Corporation $PAHC

Posted by Geri Gentry on Jun 11th, 2026

Los Angeles Capital Management LLC trimmed its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC – Free Report) by 38.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 38,444 shares of the company’s stock after selling 23,715 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.09% of Phibro Animal Health worth $1,436,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in PAHC. Vanguard Group Inc. lifted its stake in Phibro Animal Health by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock valued at $57,519,000 after acquiring an additional 13,884 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Phibro Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after purchasing an additional 21,951 shares during the last quarter. Millennium Management LLC increased its stake in shares of Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after purchasing an additional 154,281 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Phibro Animal Health by 22.5% during the 3rd quarter. Invesco Ltd. now owns 322,299 shares of the company’s stock valued at $13,040,000 after purchasing an additional 59,226 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Phibro Animal Health by 9.6% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 301,605 shares of the company’s stock valued at $12,203,000 after purchasing an additional 26,539 shares during the last quarter. Institutional investors own 99.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings lowered Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 8th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Finally, Citigroup reduced their target price on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $38.80.

Get Our Latest Report on Phibro Animal Health

Phibro Animal Health Stock Down 4.5%

Phibro Animal Health stock opened at $31.18 on Thursday. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. Phibro Animal Health Corporation has a fifty-two week low of $23.57 and a fifty-two week high of $60.08. The firm has a fifty day moving average price of $44.83 and a two-hundred day moving average price of $44.93. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of 13.38, a P/E/G ratio of 0.49 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. The business had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, analysts forecast that Phibro Animal Health Corporation will post 3.07 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be paid a $0.12 dividend. The ex-dividend date is Wednesday, June 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.5%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 20.60%.

Insider Activity

In related news, CEO Jack Bendheim sold 4,528 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total transaction of $219,562.72. Following the transaction, the chief executive officer owned 56,152 shares of the company’s stock, valued at approximately $2,722,810.48. The trade was a 7.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,928 shares of company stock valued at $4,017,273 in the last 90 days. Company insiders own 50.13% of the company’s stock.

Phibro Animal Health Profile

(Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.